Please ensure Javascript is enabled for purposes of website accessibility
Exelixis Stock Quote

Exelixis (NASDAQ: EXEL)

$17.55
(-0.3%)
-$0.06
Price as of February 3, 2023, 4:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Exelixis Returns vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
EXEL -2.23% -41.93% -10.29% +16%
S&P -7.62% +49.76% +8.40% +176%

Exelixis Company Info

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

News & Analysis

The Fool has written over 500 articles on Exelixis.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
413%
 
S&P 500 Returns
121%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 02/06/2023.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.